STOCK TITAN
  1. Home
  2. News
  3. BIOR

Biora Therapeutics Inc - BIOR STOCK NEWS

Welcome to our dedicated news page for Biora Therapeutics (Ticker: BIOR), a resource for investors and traders seeking the latest updates and insights on Biora Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biora Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biora Therapeutics's position in the market.

News
Biora Therapeutics Provides Outlook for 2024
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) provided guidance on anticipated milestones in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform. The company completed a transformation in 2023, laying the foundation for significant value inflection. The phase 1 study for BT-600, a de-risking step in NaviCap™ platform development, is underway. The company expects to progress relationships with large pharma companies for the BioJet platform, potentially providing non-dilutive funding for further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
Rhea-AI Summary
Biora Therapeutics, a biotech company listed on Nasdaq as BIOR, announced the initiation of its phase 1, first-in-human clinical study of BT-600, a drug-device combination program designed to deliver a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis. The study aims to evaluate the safety, pharmacokinetics, and pharmacodynamics of BT-600 in healthy adult volunteers, with expectations of increased colonic tissue drug levels and reduced systemic levels compared with conventional oral tofacitinib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
clinical trial
-
News
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced that its BioJet™ Systemic Oral Delivery Platform has exceeded performance targets in a preclinical study conducted in collaboration with AstraZeneca. The study demonstrated greater than 25% bioavailability compared to subcutaneous delivery, showcasing the platform's potential to deliver multi-milligram liquid doses similar to injection with minimal to no formulation changes. The company continues to generate promising results, enabling further development under the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
none
News
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announces receipt of US Patent No. 11,857,669 for targeted delivery of JAK inhibitors to the gastrointestinal tract, a significant win for its BT-600 program and NaviCap™ targeted oral delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
-
News
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced an agreement with institutional investors to reduce the company’s net debt by 60% through a convertible note exchange, bringing $16.7 million in new capital. The company has reduced its debt by $83 million in 2023, achieving a 75% overall reduction. The transaction demonstrates investor confidence in the company's innovative technologies and near-term catalysts for its NaviCap™ and BioJet™ platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none
-
News
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) announced a new research collaboration with a large pharmaceutical company to test the BioJet Systemic Oral Delivery Platform in animal models. The agreement provides funding to test the platform’s ability to achieve bioavailability through oral delivery of the collaborator’s molecules to the small intestine. The CEO, Adi Mohanty, highlighted the progress and recognition by others, stating that they are actively conducting studies with multiple collaborators and looking forward to performing studies with the big pharma collaborator in the first quarter. Biora's BioJet technology features strong patent protection and promises category-leading oral bioavailability for large molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.22%
Tags
none
News
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) has received FDA clearance for its Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis. The IND is the first active one for an ingestible drug and device combination. BT-600 utilizes Biora's NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, targeting delivery directly to the colon. The phase 1 trial will evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers receiving BT-600 with tofacitinib at 5 mg and 10 mg doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
clinical trial
-
News
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Biora Therapeutics, Inc. (Nasdaq: BIOR) provided a corporate update, reporting financial results for the third quarter and announced the advancement of their NaviCap™ Targeted Oral Delivery platform towards a phase 1 clinical trial by year-end. The BioJet™ Systemic Oral Delivery platform also shows potential for liver-targeted delivery of large molecules, with pharma collaborations accelerating. Management will host a conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
earnings
-
News
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
Rhea-AI Summary
Biora Therapeutics, Inc. will report financial results and provide a corporate update for Q3 2023. The webcast and conference call will be held on November 13, 2023, at 4:30 PM Eastern time. Dial-in and webcast details are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.52%
Tags
conferences earnings
News
Biora Therapeutics Submits Updated IND Application for BT-600
Rhea-AI Summary
Biora Therapeutics, Inc. has submitted an updated Investigational New Drug (IND) application for BT-600 to the FDA. The update includes additional information and extends the regulatory review period. BT-600 is a drug/device combination using Biora's NaviCap™ ingestible drug delivery device with a liquid formulation of tofacitinib for ulcerative colitis. The phase 1 clinical trial will evaluate safety, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
clinical trial
Stock BIOR logo
Biora Therapeutics Inc

Nasdaq:BIOR

BIOR Rankings

#5094 Ranked by Market Cap
#5308 Ranked by Stock Gains
N/A Ranked by Dividends

BIOR Stock Data

22.21M
13.75M
7.91%
64.14%
4.42%
Medical Laboratories
Health Care and Social Assistance
Link
US
San Diego

About BIOR

progenity helps patients and their families prepare for life, with medically relevant health information starting before conception, through pregnancy, childhood, and adulthood. using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.